ArticleAmerican journal of cancer research2025
Causal effect of interstitial lung disease on lung cancer risk in never-smokers and prognostic insights from Mendelian randomization and transcriptome analysis.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe relationship between interstitial lung disease (ILD) and lung cancer in nonsmokers (LCINS) has garnered increasing interest. However, the causal associations and underlying pathogenesis between ILD and LCINS remain poorly understood.
methodsThis research utilized a bidirectional two-sample Mendelian randomization (MR) method, utilizing forward MR analysis to assess the causal impact of ILD on LCINS and reverse MR analysis to evaluate the causal effect of LCINS on ILD. Additionally, transcriptome data and bioinformatics analyses were used to explore the associations between ILD and LCINS. An ILD-related gene signature (ILD risk score) was identified to examine its influence on the hallmark signaling pathways and the immune microenvironment in LCINS.
resultsThe study revealed a significant causal relationship between ILD and LCINS, with ILD increasing the risk of lung cancer in nonsmoking European populations. We developed a 5-gene risk model, which includes CD1A, CDH3, KRT6B, MMP1, and MMP10, via least absolute shrinkage and selection operator (LASSO) regression. The ILD risk score independently influences the prognosis of nonsmoking patients with lung cancer, and these five genes are also significantly associated with overall survival (OS) rates. Patients in the high-ILD risk subgroup exhibited significantly poorer survival rates. A highly accurate nomogram was developed to increase the clinical applicability of the ILD risk score. Additionally, the ILD risk scores were significantly correlated with hallmark signaling pathways and immune cell infiltration.
conclusionsThis study suggested that ILD may have a positive causal effect on LCINS, with the ILD risk score serving as an effective predictor of the prognoses in LCINS patients. It is associated with tumor proliferation and the activation of metabolism-related signaling pathways. These findings also indicate that ILD may contribute to the occurrence and progression of LCINS through its influence on immune cell infiltration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.